We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

GlaxoSmithKline and Theravance Start Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Programme

News   Jan 04, 2008

 
GlaxoSmithKline and Theravance Start Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Programme
 
 
 

RELATED ARTICLES

Better Tailored Drugs with Fewer Side-Effects

News

A recent achievement in the field of protein research allows for better tailored pharmaceuticals with fewer side-effects.

READ MORE

Scientists Develop New Drug Treatment for TB

News

Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals. The team hope the compound –developed after 10 years of painstaking research will be trialed on humans within three to four years.

READ MORE

Novel Drug Designed for Pancreatic Cancer

News

A treatment for highly aggressive and commonly fatal pancreatic cancer is being developed, reports a University of Houston researcher who has designed a new medicine that can inhibit two of the major pathways of the deadly disease.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE